Know what the market will do before your competitors
The moves that decide a launch, a franchise, or an endgame — made on ground truth, not opinion. Built for commercial leaders in life sciences.
Built for the leaders who own the number.
Launch, expansion, and defense decisions made on live evidence, not instinct or a stale deck.
Competitive, regulatory, and market threats surfaced before they reach the number.
Every decision inherits the last, so your advantage grows across the asset's whole life.
Ground Truth → World Model → Decision
We unify proprietary patient-level signal with systemic market dynamics, then simulate every plausible trajectory of your asset.
Ground Truth
Unfiltered behavioral signal from prescribers, payers, and patients. Captured upstream of the CRM — before it becomes lagging.
World Model
A live digital twin of the therapeutic landscape. Competitor moves, regulatory shifts, and market response simulated end-to-end.
Decision Layer
Ranked, specific interventions with quantified impact on NPV and share protection. Board-ready, not dashboard-ready.
Intelligence, contextual to the asset lifecycle
The signals that matter change at every stage. Each phase enriches the next — so every decision is made with the compounding intelligence of the ones before it.
Back a target you can actually win
The decision: Is this target and indication worth committing a program to?
- Synthetic patient populations and in-silico disease-progression models for the target indication — generated before any real-world data exists
- Biomarker prevalence and responder-subgroup mapping across the addressable population
- Real-time monitoring of competitor programs against the same mechanism, often surfaced ahead of public disclosure
- Evolving FDA / EMA / PMDA guidance and regulatory precedent for the pathway
- Patent and freedom-to-operate landscape around the mechanism of action
- A quantified read on whether the biology is addressable and the population is large enough to matter
- Mechanism white-space: where competitors already crowd versus where the asset could own the space
- A go / no-go asset thesis grounded in synthetic evidence and competitive reality rather than opinion
A 42% larger modeled treatment effect surfaced in a biomarker-enriched subpopulation the standard analysis would have averaged away.
The target thesis, competitor set and synthetic population become the seed the rest of the lifecycle compounds on — trial design inherits the enriched population; commercial inherits the competitive map.
The moments that decide the decade.
Asset Launch
Optimize the trajectory from day one. Model adoption, access, and payer response before the first script or first case.
Expansion
Move into new indications, segments, and geographies without cannibalizing the base. Quantify the demand shifts before you commit.
Competitive Entry
A rival launch or new clearance is coming. Simulate their playbook and pre-empt share loss with defensive moves you've already tested.
End of Runway
Every asset matures. Time your endgame against generic, biosimilar, or next-generation displacement — and carry the value into what comes next.
The future of your market is no longer a matter of opinion.
We take on the engagements where the decisions are consequential and the timing is real. Start with a briefing on your asset and your market.